Study of glucuamine specific action under conditions of diabetic nephropathy in the experiment
DOI:
https://doi.org/10.24959/ubphj.18.155Keywords:
glucuamine, quercetin, glucosamine hydrochloride, N-acetylglucosamine, diabetic nephropathyAbstract
Topicality. Diabetic nephropathy has a great medical and social importance, since it is the main cause of chronic kidney disease (CKD) and its terminal form. For today, there are no effective drugs for treatment of diabetic nephropathy
and CKD in medical practice.
Aim. Experimental study of Glucuamine specific action on the background of diabetic nephropathy development in order to substantiate the feasibility of its using in CKD therapy.
Materials and methods. The study were carried out on the model of diabetic nephropathy, which was caused by intraperitoneal administration of alloxan at the dose 200 mg/kg using 56 rats. There was urine studied in animals, the
kidney mass coefficient, the glomerular filtration rate (GFR), the index of tubular reabsorption, the total protein, glucose, creatinine and urea in the blood were determined.
Results and discussion. Under the Glucuamine influence on the 90th day of the study there was a significant decrease in the level of proteinuria, the kidney mass index and an increase in the relative diuresis and GFR, which indicates the normalization of the functional state of the kidneys. There was also an increase the total protein content in animals’ blood as well as a decrease in creatinine and urea, which indicates an improvement in protein and ni-trogen metabolism. At the same time according to the degree of influence, Glucuamine drug was superior in comparative activity of quercetin and lespephril.
Conclusions. Under conditions of nephropathy development on the background of diabetes mellitus type I in rats Glucuamine exerts a pronounced nephroprotective and hypo-azotemic action and it is a promising drug for CKD therapy.
References
Pyrih, L. A., Ivanov, D. D. (2014). Nefrolohiia. Donetsk: Vydavets Zaslavskyi, 292.
Skvortcov, V. V., Tumarenko, A. V. (2017). Klinicheskaia nefrologiia. Sankt–Petersburg: SpetcLit, 199.
Kolesnyk, M. O., Saidakova, N. O., Kozliuk, N. I. et al. (2017). Ukrainskyi zhurnal nefrolohii ta dializu, 1 (53), 3–12.
Shebeko, S. K., Zupanets, I. A. (2006). Klinichna farmatsiia – Clinical Pharmacy, 10 (2), 31–35.
Zupanets, I. A., Shebeko, S. K. (2007). Medychna khimiia, 9 (1), 67–71.
Zupanets, I. A., Shebeko, S. K., Kharchenko, D. S. (2009). Visnyk farmatsii – News of Pharmacy, 2, 75–78.
Kharchenko, D. S. (2009). The research of quercetin parenteral form influence on the course of experimental glomerulonephritis. Drug Information
Journal, 2 (43), 228–229.
Shebeko, S. K. (2017). Ukrainskyi biofarmatsevtychnyi zhurnal – Ukrainian biopharmaceutical journal, 5, 40–44.
Guide for the care and use of laboratory animals, 8th edition. (2011). Washington: The National Academies Press, 246.
European convention for the protection of vertebrate animals used for experimental and other scientific purpose: Council of Europe (1986). Strasbourg, 52.
Shtryhol, S. Yu., Lisovyi V. M., Zupanets I. A. et al. (2009). Metody eksperymentalnoho modeliuvannia urazhennia nyrok dlia farmakolohichnykh
doslidzhen. Kharkiv: NUPh, 48.
Shebeko, S. K. (2017). Liky Ukrainy plius, 4, 26–29.
Stefanov, A. V. (2002). Doklinicheskie issledovaniia lekarstvennykh sredstv. Kiev: Avitcenna, 528.
Dolgov, V. V., Menshikov V. V. (2012). Klinicheskaia laboratornaia diagnostika. Moscow: GEOTAR–Media, 928.
Kamyshnikov, V. S. (2011). Metody klinicheskikh laboratornykh issledovanii. Moscow: MEDpress–inform, 752.
Trukhacheva, N. V. (2012). Matematicheskaia statistika v mediko–biologicheskikh issledovaniiakh s primeneniem paketa Statistica. Moscow: GEOTAR– Media, 379.
Downloads
Published
Issue
Section
License
Copyright (c) 2018 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
